Key terms

About ALC

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ALC news

Apr 08 6:04am ET Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Alcon (ALC) and Teladoc (TDOC) Apr 04 5:20am ET Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Cabaletta Bio (CABA) Mar 19 8:15am ET Alcon’s Growth Trajectory: Buy Rating Affirmed Amidst Upcoming Product Launch and Market Share Expansion Mar 14 3:25am ET Alcon (ALC) Has a New Rating from RBC Capital Mar 08 12:04pm ET Alcon price target raised to CHF 87 from CHF 78 at UBS Mar 08 4:26am ET UBS Sticks to Its Buy Rating for Alcon (ALC) Mar 06 9:58am ET Alcon reports Vivity exceeds over one million implants worldwide Mar 05 8:30am ET Analysts’ Top Healthcare Picks: Avadel Pharmaceuticals (AVDL), Alcon (ALC) Mar 04 8:12am ET Alcon price target raised to $100 from $90 at Argus Mar 01 7:29am ET Alcon price target raised to $100 from $95 at Mizuho Mar 01 1:31am ET Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Alcon (ALC) and Sarepta Therapeutics (SRPT) Feb 29 2:42pm ET Alcon price target raised to CHF 85.10 from CHF 74.40 at JPMorgan Feb 29 7:10am ET Alcon price target raised to $96.60 from $93 at Bernstein Feb 29 6:47am ET Alcon price target raised to $95 from $92 at Baird Feb 29 5:36am ET Buy Rating for Alcon: Projected Market Outperformance and Margin Expansion Feb 29 2:36am ET Alcon’s Strong Financial Outlook and Growth Potential Affirm Outperform Rating Feb 28 7:02am ET Analysts Are Bullish on Top Healthcare Stocks: Alcon (ALC), Xencor (XNCR) Feb 28 4:25am ET Alcon (ALC) Gets a Buy from UBS Feb 27 7:25pm ET Alcon’s Strong Financial Performance and Market Share Growth Merit a Buy Rating Feb 27 4:31pm ET Alcon sees FY24 core EPS $3.00-$3.10, consensus $3.04 Feb 27 4:31pm ET Alcon reports Q4 core EPS 70c, consensus 68c Feb 22 7:40am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Alcon (ALC) and Outset Medical (OM) Feb 07 7:29am ET Alcon’s Strategic Growth in the Ophthalmic Market Bolstered by Promising AR-15512 Treatment: A Buy Rating Overview Feb 06 9:55am ET Tesla downgraded, UPS upgraded: Wall Street’s top analyst calls Feb 06 4:46am ET Alcon resumed with an Overweight at KeyBanc Feb 01 12:40am ET Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Alcon (ALC) Jan 23 5:09am ET Alcon initiated with an Outperform at Bernstein Jan 22 1:30pm ET Alcon price target raised to CHF 85 from CHF 80 at Deutsche Bank Jan 12 5:46am ET Buy Rating Justified: Alcon’s Strong 2024 Outlook and Promising Drug Pipeline Signal Robust Financial Future Jan 09 4:31pm ET Alcon reports ‘positive’ topline results from Phase 3 COMET trials of AR-15512 Jan 09 4:50am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Tecan Group AG (OtherTCHBF)

No recent press releases are available for ALC

ALC Financials

1-year income & revenue

Key terms

ALC Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ALC Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms